Immune-Onc Therapeutics
Sydney Ray has over 13 years of work experience in the clinical research field. Sydney began their career in 2007 at the University of Chicago Medical Center as a Clinical Research Project Coordinator. In 2010, they moved to Boston University School of Medicine as a Project Manager/ Clinical Research Coordinator. Sydney then worked at Novartis Vaccines and Diagnostics as a Clinical Trial Associate in 2013. In 2014, they joined Harvard Clinical Research Institute as a Clinical Research Associate II. In 2016, they moved to Novartis as a Clinical Trial Manager and Senior Clinical Research Associate. Most recently, in 2021, they began working at Immune-Onc Therapeutics as a Senior Clinical Trial Manager.
Sydney Ray attended the University of Wisconsin-Madison from 2003 to 2007 and earned a Bachelor's Degree in Biochemistry and Molecular Biology. Sydney then attended Boston University from 2010 to present and is currently pursuing a Master's Degree in School of Public Health.
This person is not in any offices
Immune-Onc Therapeutics
Immune-Onc Therapeutics, Inc. (“Immune-Onc”) is a clinical-stage cancer immunotherapy company dedicated to the discovery and development of novel myeloid checkpoint inhibitors for cancer patients. Headquartered in Palo Alto, California, Immune-Onc has assembled a diverse team with deep expertise in drug development and proven track records of success at leading biotechnology companies.